Acetate salt of buprenorphine and methods for preparing buprenorphine
The present disclosure provides acetate salts of buprenorphine, and its anhydrates, solvates, hydrates, and crystalline forms thereof, where the acetate salts of buprenorphine are essentially free of impurities. The disclosure further provides method of preparing the acetate salts, buprenorphine free base prepared from the acetate salts, other salts prepared from the free base, and pharmaceutical compositions thereof essentially free of impurities.
1. A method for preparing buprenorphine free base, comprising treating an acetate salt of buprenorphine at a pressure from about 50 Torr to about 250 Torr, inclusive, and a temperature, wherein the temperature of the acetate salt of buprenorphine is at least about 30° C., for a period of time sufficient to form buprenorphine free base.
2. The method of claim 1 , wherein the pressure ranges from about 100 Torr to about 200 Torr, inclusive and the period of time is at least about 1 hour.
3. The method of claim 2 , wherein the temperature is at least about 50° C. and the period of time is at least about 10 hours.
4. The method of claim 2 , wherein the temperature is at least about 65° C. and the period of time is at least about 5 hours.
5. The method of claim 1 , further comprising slurrying the buprenorphine free base with a slurrying solution comprising water and an alcohol, and filtering the buprenorphine free base therefrom wherein the temperature during the slurrying and the filtering is at least about 50° C.
6. The method of claim 1 , wherein acetic acid is present in the buprenorphine free base in an amount of less than about 0.5 wt % relative to the buprenorphine free base.
7. The method of claim 1 , further comprising isolating a buprenorphine free base product, wherein the buprenorphine free base product comprises about 0.08 wt % or less of a compound of formula (12):
8. The method of claim 7 , further comprising forming a pharmaceutical composition comprising the buprenorphine free base product and a pharmaceutically acceptable carrier.